365 related articles for article (PubMed ID: 24762075)
1. Optimizing NKT cell ligands as vaccine adjuvants.
Carreño LJ; Kharkwal SS; Porcelli SA
Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
[TBL] [Abstract][Full Text] [Related]
2. Glycolipid activators of invariant NKT cells as vaccine adjuvants.
Kharkwal SS; Arora P; Porcelli SA
Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623
[TBL] [Abstract][Full Text] [Related]
3. Harnessing invariant NKT cells in vaccination strategies.
Cerundolo V; Silk JD; Masri SH; Salio M
Nat Rev Immunol; 2009 Jan; 9(1):28-38. PubMed ID: 19079136
[TBL] [Abstract][Full Text] [Related]
4. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
5. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
7. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.
Venkataswamy MM; Porcelli SA
Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice.
Freigang S; Zadorozhny V; McKinney MK; Krebs P; Herro R; Pawlak J; Kain L; Schrantz N; Masuda K; Liu Y; Savage PB; Bendelac A; Cravatt BF; Teyton L
J Clin Invest; 2010 Jun; 120(6):1873-84. PubMed ID: 20484813
[TBL] [Abstract][Full Text] [Related]
9. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.
Venkataswamy MM; Ng TW; Kharkwal SS; Carreño LJ; Johnson AJ; Kunnath-Velayudhan S; Liu Z; Bittman R; Jervis PJ; Cox LR; Besra GS; Wen X; Yuan W; Tsuji M; Li X; Ho DD; Chan J; Lee S; Frothingham R; Haynes BF; Panas MW; Gillard GO; Sixsmith JD; Korioth-Schmitz B; Schmitz JE; Larsen MH; Jacobs WR; Porcelli SA
PLoS One; 2014; 9(9):e108383. PubMed ID: 25255287
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
Padte NN; Li X; Tsuji M; Vasan S
Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784
[TBL] [Abstract][Full Text] [Related]
11. Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface.
Brennan PJ; Cheng TY; Pellicci DG; Watts GFM; Veerapen N; Young DC; Rossjohn J; Besra GS; Godfrey DI; Brenner MB; Moody DB
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8348-8353. PubMed ID: 28716901
[TBL] [Abstract][Full Text] [Related]
12. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].
Watarai H; Tashiro T; Chiba T; Taniguchi M
Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371
[No Abstract] [Full Text] [Related]
13. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.
Van Kaer L; Parekh VV; Wu L
Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558
[TBL] [Abstract][Full Text] [Related]
14. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
15. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
16. The ins and outs of type I iNKT cell development.
Shissler SC; Webb TJ
Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719
[TBL] [Abstract][Full Text] [Related]
17. Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids.
Shimamura M; Yamamura M; Nabeshima T; Kitano N; van den Elzen P; Yesilkaya H; Andrew P; Illarionov P
Sci Rep; 2017 Aug; 7(1):9703. PubMed ID: 28852174
[TBL] [Abstract][Full Text] [Related]
18. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
19. Scavenger receptors target glycolipids for natural killer T cell activation.
Freigang S; Landais E; Zadorozhny V; Kain L; Yoshida K; Liu Y; Deng S; Palinski W; Savage PB; Bendelac A; Teyton L
J Clin Invest; 2012 Nov; 122(11):3943-54. PubMed ID: 23064364
[TBL] [Abstract][Full Text] [Related]
20. Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.
Veerapen N; Kharkwal SS; Jervis P; Bhowruth V; Besra AK; North SJ; Haslam SM; Dell A; Hobrath J; Quaid PJ; Moynihan PJ; Cox LR; Kharkwal H; Zauderer M; Besra GS; Porcelli SA
Bioconjug Chem; 2018 Sep; 29(9):3161-3173. PubMed ID: 30085659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
